PrEP Considerations for Transgender and Nonbinary Individuals
Providing gender-affirming care is a key step in effectively increasing PrEP uptake for transgender individuals.
Decera Clinical Education Infectious Disease Podcast · Jill Blumenthal MD MAS
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:
- Providing gender-affirming care
- Integrating PrEP and gender care
- Taking a sexual history and addressing sexual health
- PrEP efficacy and options for transgender individuals, including FTC/TDF, FTC/TAF, and long-acting CAB
- The importance of reassuring transgender individuals that data suggest there are no drug–drug interactions between gender-affirming hormone therapy and any of the PrEP options
Jill Blumenthal, MD, MAS (she/hers)
Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California
See the full program at:
https://bit.ly/3WhbBvZ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.